What one share of CAMP4 Therapeutics holds
We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases.
CAMP4 Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.09 |
|---|---|
| Profit | −$2.18 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.58 |
| Cash and investments | $1.66 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.89 | −$124.79 | $1.72 | −$113.51 | — | −$268.57 |
| 2024 | $0.14 | −$11.04 | $0.09 | −$9.81 | $0.00 | — |
| 2025 | $0.12 | −$2.65 | $0.01 | −$0.98 | $0.00 | $0.92 |
Common questions about CAMP4 Therapeutics
How much does one share of CAMP4 Therapeutics earn?
Over the last 12 months, CAMP4 Therapeutics lost $2.18 for each share on $0.09 of sales.
Does CAMP4 Therapeutics pay a dividend?
CAMP4 Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is CAMP4 Therapeutics’s book value per share?
CAMP4 Therapeutics’s book value is negative (−$0.01 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of CAMP4 Therapeutics have?
Each share of CAMP4 Therapeutics has $1.66 of cash and investments, as of June 30, 2026.
What is CAMP4 Therapeutics’s free cash flow per share?
−$0.58 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.